Contract End Date and Amount Subject to Change by Mutual Agreement
Samsung Biologics has signed a contract for contract manufacturing of pharmaceuticals worth approximately 102.4 billion KRW.
On June 10, Samsung Biologics announced that it had signed a contract worth approximately 102,450,590,000 KRW (75,392,300 USD) with a pharmaceutical company based in Europe.
The contract period runs from this day until December 31, 2031. There is no down payment or advance payment, and both the contract end date and contract amount may be subject to change by mutual agreement between the two companies. The identity of the contracting party will be disclosed on December 31, 2031, due to business confidentiality reasons, and this date may also be subject to change in the future.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
